Today's Research Report Coverage on Medical Supplies Stocks -- DENTSPLY SIRONA, Antares Pharma, Integra LifeSciences, and Baxter

Thursday, November 9, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Nov. 9, 2017 /PRNewswire/ -- If you want a Stock Review on XRAY, ATRS, IART, or BAX then come over to

and sign up for your free customized report. IBISWorld reported that over the five years to 2022, it expects US Medical Instruments and Supplies Manufacturing industry revenues to return to growth. In particular, as healthcare reform expands healthcare
coverage, some traditionally underserved demographics will gain access to care. Today, covers the performance of DENTSPLY SIRONA Inc. (NASDAQ: XRAY), Antares Pharma Inc. (NASDAQ: ATRS), Integra LifeSciences Holdings Corp. (NASDAQ: IART), and Baxter International Inc. (NYSE: BAX). Learn more about these stocks by signing up for their free reports on at:


On Wednesday, shares in York, Pennsylvania headquartered DENTSPLY SIRONA Inc. recorded a trading volume of 1.72 million shares. The stock ended the session 0.20% higher at $64.51. The Company's shares have gained 12.05% in the last one month, 16.23% over the previous three months, and 11.74% on an YTD basis. The stock is trading 8.97% above its 50-day moving average and 5.61% above its 200-day moving average. Moreover, shares of DENTSPLY SIRONA, which designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide, have a Relative Strength Index (RSI) of 69.03.  

On October 16th, 2017, DENTSPLY SIRONA announced the appointment of Nick Alexos as EVP, Chief Administrative Officer, reporting directly to Mark Thierer, Interim CEO, effective immediately. Thierer will lead Treasury, Information Technology, Business Development, Strategic Planning, and Investor Relations. Additionally, Keith Ebling joins as EVP, General Counsel & Secretary, also reporting to Mark Thierer, effective immediately. Ebling replaces Jonathan Friedman, who resigned from the Company.

On November 06th, 2017, research firm Barrington Research upgraded the Company's stock rating from 'Market Perform' to 'Outperform', with a target price of $73 per share. The free research report on XRAY is available at:

Antares Pharma

Ewing, New Jersey headquartered Antares Pharma Inc.'s stock closed the day 8.94% lower at $1.63. A total volume of 3.15 million shares was traded, which was above their three months average volume of 2.21 million shares. The Company's shares are trading 41.57% below their 50-day moving average. Additionally, shares of Antares Pharma, which focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide, have an RSI of 26.98.  

On October 20th, 2017, Antares Pharma announced that it has received a Complete Response Letter (CRL) from the US FDA regarding the New Drug Application (NDA) for XYOSTED™ (testosterone enanthate) injection. The CRL indicates that the FDA cannot approve the NDA in its present form. Based on findings in studies QST-13-003 and QST-15-005, the FDA is concerned that XYOSTED™ could cause a clinically meaningful increase in blood pressure. It also raised a concern regarding the occurrence of depression and suicidality. 

On October 23rd, 2017, research firm H.C. Wainwright reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $5 a share to $3.50 a share. The complimentary report on ATRS can be downloaded at:

Integra LifeSciences Holdings

Shares in Plainsboro, New Jersey headquartered Integra LifeSciences Holdings Corp. recorded a trading volume of 601,582 shares. The stock ended yesterday's trading session 1.87% higher at $48.45. The Company's shares have advanced 12.95% on an YTD basis. The stock is trading above its 200-day moving average by 1.11%. Furthermore, shares of Integra LifeSciences have an RSI of 45.21.  

On October 26th, 2017, Integra LifeSciences reported financial results for Q3 ended September 30th, 2017. Revenue for Q3 2017 increased to $278.8 million, GAAP net income was $3.2 million, and cash flow from operations was $45.2 million. Adjusted EBITDA for the quarter was $63.0 million, and adjusted net income was $36.1 million. Visit us today and download our complete research report on IART for free at:

Baxter International

Deerfield, Illinois headquartered Baxter International Inc.'s stock finished Wednesday's session 1.07% higher at $65.01 with a total trading volume of 1.89 million shares. The Company's shares have advanced 5.35% in the last one month, 8.88% over the previous three months, and 46.62% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 2.56% and 12.61%, respectively. Additionally, shares of Baxter have an RSI of 58.11.  

On November 01st, 2017, Baxter announced a new PD-first program for its employees and family members aimed at improving education and awareness of dialysis treatment options, including peritoneal dialysis (PD). PD is a form of dialysis that is performed by the patient while at home, often at night while the patient sleeps. Working with its health plan administrator, the Company will offer the PD-first program to its US employees and their covered family members starting January 01st, 2018. Get free access to your technical report on BAX at:


Daily Stock Tracker:

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email:  Phone number:  (207)331-3313Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

View original content:



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store